# CNS SPECTRUMS

The International Journal of Neuropsychiatric Medicine

## **ACADEMIC SUPPLEMENT**

Optimizing Treatment for Patients With Schizophrenia: Targeting Positive Outcomes

Introduction D.E. Casey

The Science of Antipsychotics: Mechanistic Insight C.A. Tamminga

Management of Acute Psychosis: From Emergency to Stabilization D.L. Zimbroff

Beyond Control of Acute Exacerbation: Enhancing Affective and Cognitive Outcomes H.Y. Meltzer

Obesity, Diabetes, and Metabolic Syndrome: New Challenges in Antipsychotic Drug Therapy E. Caballero

Factors in Antipsychotic Drug Selection: Tolerability Considerations H.A. Nasrallah

Long-Term Treatment Goals: Enhancing Healthy Outcomes D.E. Casey

# 

### The International Journal of Neuropsychiatric Medicine

Jack M. Gorman, MD Mount Sinai School of Medicine New York, NY

#### ASSOCIATE AND FOUNDING EDITOR

Eric Hollander, MD Mount Sinai School of Medicine New York, NY

### INTERNATIONAL EDITOR

Joseph Zohar, MD Chaim Sheba Medical Center Tel-Hashomer, Israel

#### ASSOCIATE INTERNATIONAL EDITORS **EUROPE**

Donatella Marazziti, MD University of Pisa Pisa, Italy

#### **MID-ATLANTIC**

Dan J. Stein, MD, PhD University of Stellenbosch Tygerberg, South Africa

Shigeto Yamawaki, MD, PhD Hiroshima University School of Medicine Hiroshima, Japan

#### **MEDICAL REVIEWER**

David L. Ginsberg, MD New York University Medical Center New York, NY

#### **BOARD OF ADVISORS**

### **NEUROLOGISTS**

Los Angeles, CA

Mitchell F. Brin, MD University of California, Irvine Irvine, CA Jeffrey L. Cummings, MD University of California, Los Angeles Los Angeles, CA Jerome Engel, Jr., MD, PhD University of California, Los Angeles Mark S. George, MD Medical University of South Carolina Charleston, SC

Richard B. Lipton, MD

Albert Einstein College of Medicine

C. Warren Olanow, MD, FRCPC Mount Sinai School of Medicine New York, NY

Steven George Pavlakis, MD Maimonides Medical Center Brooklyn, NY

Stephen D. Silberstein, MD, FACP Thomas Jefferson University Philadelphia, PA

Michael Trimble, MD, FRCP, FRPsych National Hospital for Neurology and Neurosurgery London, United Kingdom

#### **PSYCHIATRISTS**

Margaret Altemus, MD Cornell University Medical College New York, NY Dennis S. Charney, MD National Institute of Mental Health Bethesda, MD Dwight L. Evans, MD University of Pennsylvania Philadelphia, PA

Siegfried Kasper, MD University of Vienna Vienna, Austria Martin B. Keller, MD Brown Medical School Providence, RI

Lorrin M. Koran, MD Stanford University School of Medicine Stanford, CA

Yves Lecrubier, MD Hôpital de la Salpêtrière Paris, France

Herbert Y. Meltzer, MD Vanderbilt University Medical Center Nashville, TN

Stuart A. Montgomery, MD St. Mary's Hospital Medical School London, United Kingdom Charles B. Nemeroff, MD, PhD

Emory University School of Medicine Atlanta, GA

Humberto Nicolini, MD, PhD National Mexican Institute of **Psychiatry** 

Mexico City, Mexico Stefano Pallanti, MD, PhD University of Florence Florence, Italy

Katharine Phillips, MD Brown Medical School Providence, RI

Harold A. Pincus, MD Western Psychiatric Institute & Clinic RAND-University of Pittsburgh Health Institute, Pittsburgh, PA

Scott L. Rauch, MD Massachusetts General Hospital Charlestown, MA

Alan F. Schatzberg, MD Stanford University School of Medicine Stanford, CA

Thomas E. Schlaepfer, MD University of Bonn Bonn, Germany

Stephen M. Stahl, MD, PhD University of California, San Diego La Jolla, California

Norman Sussman, MD, DFAPA **New York University Medical School** New York, NY

Karen Dineen Wagner, MD, PhD The University of Texas Medical Branch Galveston, TX

Herman G.M. Westenberg, MD University Hospital Utrecht Utrecht, The Netherlands Stuart C. Yudofsky, MD Baylor College of Medicine Houston, TX

#### **MBL COMMUNICATIONS** Corporate Staff

**CEO & PUBLISHER** Darren L. Brodeur **ASSOCIATE PUBLISHER** Elizabeth Katz MANAGING EDITOR Christopher Naccari SENIOR EDITOR **Deborah Hughes DEPUTY SENIOR EDITOR** 

**ACQUISITIONS EDITOR** Lisa Arrington
ASSISTANT ACQUISITIONS EDITOR

Eileen S. Seligman

**EDITORIAL ASSISTANT** Shelley Wong

PRODUCTION MANAGER Lila Moses

**GRAPHIC DESIGNER** Anthony J. Korsak

CONTROLLER John Spano

NATIONAL ACCOUNT MANAGER

Kelly J. Staley

INFORMATION TECHNOLOGY

Greg Taube **OFFICE MANAGER** 

Claudette Crawford **OFFICE ASSISTANT** Manuel Pavón

**CORPORATION COUNSEL** 

# Lawrence Ross, Esq. Bressler, Amery, and Ross

#### **EDITORIAL MISSION**

José R. Ralat

CNS Spectrums' editorial mission is to address relevant neuropsychiatric topics, including the prevalence of comorbid diseases among patients, and original research and reports that emphasize the profound diagnostic and physiologic connections made within the neurologic and psychiatric fields. The journal's goal is to serve as a resource to psychiatrists and neurologists seeking to understand and treat disturbances of cognition, emotion, and behavior as a direct consequence of central nervous system disease, illness, or trauma.

# CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

## **Table of Contents**

November 2003 Volume 8 - Number 11 - Supplement 2

Based on Proceedings From the American Psychiatric Association Meeting Held May 17–22, 2003, in San Francisco, California

4 Introduction: Optimizing Treatment for Patients With Schizophrenia

By Daniel E. Casey, MD

- 5 The Science of Antipsychotics: Mechanistic Insight By Carol A. Tamminga, MD
- 10 Management of Acute Psychosis: From Emergency to Stabilization By Dan L. Zimbroff, MD
- 16 Beyond Control of Acute Exacerbation: Enhancing Affective and Cognitive Outcomes By Herbert Y. Meltzer, MD
- 19 Obesity, Diabetes, and Metabolic Syndrome: New Challenges in Antipsychotic Drug Therapy By Enrique Caballero, MD
- Factors in Antipsychotic Drug Selection:Tolerability ConsiderationsBy Henry A. Nasrallah, MD
- **26** Long-Term Treatment Goals: Enhancing Healthy Outcomes By Daniel E. Casey, MD

#### **CONTINUING MEDICAL EDUCATION**

29 This CME quiz on schizophrenia is accredited by Mount Sinai School of Medicine for 3 credit hours in Category 1.

**CNS Spectrums** is an Index Medicus journal and is available on MEDLINE under the citation CNS Spectr.

It is also indexed by DIALOG, EMBASE/Excerpta Medica, OVID, Lexis-Nexis, and SilverPlatter.

CNS Spectrums®

(ISSN 1092-8529) is published monthly by MBL Communications, Inc. 333 Hudson Street, 7th Floor New York, NY 10013

One year subscription rates: domestic \$120; foreign \$185; in-training \$75. For subscriptions, Fax: 212-328-0600 Web site: www.cnsspectrums.com

For editorial inquiries: dh@mblcommunications.com

Postmaster: Send address changes to CNS Spectrums c/o PPS Medical Marketing Group 264 Passaic Avenue Fairfield, NJ 07004-2595

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., or the editorial advisory board.

CNS Spectrums® is a registered trademark of CNS Spectrums, LLC, New York, NY.

Permission to reproduce articles in whole or in part must be obtained in writing from the publisher.



Copyright ©2003 by MBL Communications, Inc. All rights reserved.

Printed in the United States.

\_\_\_\_\_Disclai

This academic supplement is supported via an unrestricted educational grant from Pfizer Inc. Sponsorship of this review does not imply the sponsor's agreement with the views expressed herein.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher, the sponsor, nor the authors can be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound currently under clinical investigation.

In an effort to allow for the widest distribution of these guidelines, the authors have modified the originally printed material to more closely conform to the limitations of product labeling. For many of the drugs discussed herein, initiation at lower doses may increase tolerability and efficacy.